Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis

Weiquan Lu1, Madhuri Bhasin, Stella E Tsirka

  • 1Program in Pharmacology, Department of Pharmacological Sciences, University Medical Center at Stony Brook, Stony Brook, New York 11794-8651, USA.

Insights

Tissue plasminogen activator (tPA) plays a dual role in multiple sclerosis (MS) models. While tPA exacerbates early disease, it aids recovery, suggesting therapeutic potential.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Multiple sclerosis (MS) is characterized by inflammation, demyelination, and neurodegeneration.
  • Tissue plasminogen activator (tPA) is upregulated in MS brains, but its role remains unclear.
  • tPA influences neuronal plasticity, cell death, and microglial activation in the central nervous system (CNS).

Purpose of the Study:

  • To investigate the role of tPA in experimental allergic encephalomyelitis (EAE), a model for MS.
  • To examine the impact of tPA deficiency on EAE progression and neuropathology.

Main Methods:

  • Induction of EAE in wild-type and tPA-deficient (tPA(-/-)) mice.
  • Assessment of clinical EAE scores, demyelination, axon degeneration, microglial activation, and chemokine production.

Main Results:

  • Mice lacking tPA (tPA(-/-)) showed delayed EAE onset but increased disease severity and delayed recovery.
  • Demyelination and axon degeneration were delayed in tPA(-/-) mice.
  • Microglial activation and chemokine production were attenuated in tPA(-/-) mice.

Conclusions:

  • tPA and microglia have complex, time-dependent roles in MS/EAE pathogenesis.
  • tPA activity appears detrimental during EAE onset but beneficial during the recovery phase.
  • Targeting tPA activity temporally may offer a therapeutic strategy for managing MS.